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Abstract
Purpose People with personality disorders have significantly reduced life expectancy and increased rates of cardiovascular 
disease compared to members of the general population. Given that more people die annually of cardiovascular disease 
across the globe than from any other cause, it is important to identify the evidence for interventions aimed at improving 
cardiovascular health among people with personality disorders.
Methods Systematic literature review. PsycINFO, MEDLINE and EMBASE were searched using NICE Healthcare Data-
bases, as well as CENTRAL and trial registries. We sought to identify randomised controlled trials of interventions pertaining 
to adults with a primary diagnosis of personality disorder, where the primary outcome measure was cardiovascular health 
before and after the intervention.
Results A total of 1740 records were identified and screened by two independent reviewers. No papers meeting the inclu-
sion criteria were identified.
Conclusions This systematic review did not identify any randomised controlled trials testing interventions aimed at improv-
ing the cardiovascular health of people with personality disorders. Research in this area could have important public health 
implications, spanning the fields of psychiatry and general medicine.
Keywords Personality disorders · Cardiovascular health · Systematic review
Background
Personality disorders (PDs) are complex mental health prob-
lems, with an overall estimated prevalence in western Euro-
pean countries of approximately 6% [1], affecting as many 
as 40% of those in contact with secondary mental health 
services [2]. The Diagnostic and Statistical Manual of Men-
tal Disorders (DSM) classification of personality disorders 
into three clusters is widely used; Cluster A includes the 
paranoid, schizoid and schizotypal categories, Cluster B 
includes the antisocial, borderline, histrionic and narcissis-
tic categories, and Cluster C includes the avoidant, depend-
ent and obsessive–compulsive categories [3]. Although this 
review aims to include people with any type of personality 
disorder, much of the relevant epidemiological research has 
been conducted in people with Cluster B PDs, and specifi-
cally borderline personality disorder (BPD).
People with PD have a lower average life expectancy than 
the general population, with figures ranging from 18 years 
fewer in a London-based retrospective cohort study [4] to as 
many as 27.5 years for people with severe PD in a Scottish 
cohort [5]. This loss of life years cannot simply be attrib-
uted to excess rates of suicide [6, 7]. A recent review of the 
literature relating to physical health problems experienced 
by people with PD has summarised associations with pain 
conditions, obesity and chronic illnesses including CVDs 
[8]. The authors of this review found that, compared to con-
trols, people diagnosed with Cluster B PDs were at increased 
risk of experiencing syncope, seizures and arthritis, as well 
as elevated levels of health concern in general [8]. It was 
also noted that people with PD experience faster annual 
rates of health decline (by 50%) from adolescence to their 
mid-30 s compared to controls [8]. These health problems 
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are associated with increased health service utilisation com-
pared to the general population [9, 10]. Other research has 
found differences in hospitalisation rates among people with 
borderline PD compared to controls which were especially 
apparent in relation to cardiac and gynaecological condi-
tions [11].1
According to the World Health Organization (WHO), 
more people die annually from cardiovascular diseases 
(CVDs) across the globe than from any other cause. CVDs 
include coronary heart disease, cerebrovascular disease 
and peripheral arterial disease [12]. In addition to the well-
known occurrence of psychiatric co-morbidities in people 
with PD [13], the disproportionately high burden of physi-
cal health problems, such as CVDs, is becoming increas-
ingly recognised as contributory to the stark reduction in life 
expectancy in this group [4, 14–16]. Moreover, the finding 
that physical illnesses predict death by suicide illustrates 
the critical interplay between poor physical health and sui-
cide among people with PD [13, 17, 18]. Evidence for an 
association between PD and CVDs comes from various 
population-based epidemiological studies, which, for BPD, 
demonstrate adjusted odds ratios for CVD ranging from 1.47 
to 7.2 [19–21]. In a UK household survey (n = 8580), Moran 
et al. found that people with a PD were almost twice as likely 
to report a history of stroke, and around 1.4 times as likely to 
report a history of ischaemic heart disease compared to the 
general population, after adjustment for age, sex, socioeco-
nomic status, hypertension, diabetes, smoking and alcohol 
use [21]. Similar figures come from the National Epidemio-
logic Survey on Alcohol and Related Conditions (NESARC) 
(n = 34,653), conducted in the United States, in which older 
adults with any PD were 1.26 times more likely to report 
a history of coronary heart disease than controls [22]. The 
longitudinal Baltimore study, in which 244 people with PD 
were followed up over a 23-year period, found that Cluster B 
disorders were consistently associated with increased CVD 
incidence, and that their presence predicted CVD mortality 
[20]. Furthermore, in a small sample of women with BPD 
(n = 47), common carotid artery ultrasound scanning demon-
strated greater intima-media thickness (compared to healthy 
controls), an early marker for atherosclerosis and subsequent 
CVD risk [23].
When considering the psychopathology associated with 
PD, the susceptibility to certain cardiovascular risk factors is 
perhaps unsurprising. People with BPD, with its association 
with early life adversity and tendency towards impulsivity, 
have been found to have an increased risk of metabolic syn-
drome and dysregulated glucose and lipid metabolism [24], 
as well as higher rates of obesity [9, 25]. Interestingly and 
perhaps intuitively, rates of smoking, alcohol consumption 
and lack of regular exercise have been found to be higher in 
non-recovered patients with BPD compared to those who 
had recovered [9]. An Australian cross-sectional study of 
young community-dwelling adults (n = 1520) also found 
strong independent associations between Cluster B PDs and 
smoking [26].
The WHO, like many national-level organisations, 
emphasises that most CVDs can be prevented by address-
ing behavioural risk factors such as tobacco smoking, poor 
diet, obesity and lack of exercise [12]. These factors, as well 
as elevated blood glucose levels and hyperlipidaemia, are 
recognised as being causally linked to CVD [27]. However, 
it cannot be assumed that the usual CVD risk reduction strat-
egies are generalisable to people with PD; in this group, 
compared to the general population, important differences 
regarding patterns of healthcare utilisation [28], treatment 
adherence [29], and co-morbidities [30] must all be con-
sidered. We chose to carry out this systematic review as 
targeted interventions in this area are likely to provide an 
important avenue to narrow the health and life expectancy 
gap faced by people with PDs.
Objectives
1. To assess whether any interventions designed to improve 
the cardiovascular health or cardiovascular risk factors 
in people diagnosed with PDs have been developed and 
evaluated using randomised controlled trials (RCTs).
2. To assess whether any such interventions are efficacious.
Methods
Search strategy and selection criteria
This systematic review was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [31].
We searched for RCTs of interventions aimed at improv-
ing cardiovascular disease or improving cardiovascular risk 
factors in people with a primary diagnosis of PD.
Inclusion criteria
Trials were eligible for inclusion if they met the following 
criteria: [1] used random allocation to assign participants 
to the intervention and control groups; [2] all participants 
were adults (aged 18–65 years) with a primary diagnosis of 
any type of PD, irrespective of the diagnostic criteria used.
1 The authors do note that the increased presentation to cardiology 
departments may be confounded by the co-occurrence of anxiety dis-
orders in patients with BPD.
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We set out to include studies of any intervention aimed at 
improving cardiovascular disease or improving cardiovascu-
lar risk factors. This would include studies aimed at promot-
ing smoking cessation, increasing levels of physical activity, 
reducing weight or body mass index (BMI), improving diet, 
improving blood pressure, blood glucose or blood lipid lev-
els. Studies aimed at increasing physical health monitoring 
or access to physical healthcare which may improve cardio-
vascular health would also be included.
Outcomes
Primary outcome
Cardiovascular health, measured by 10-year CVD risk, 
cardiovascular mortality, number of cardiovascular events 
such as myocardial infarction or stroke, or any relevant 
measure of cardiovascular health quoted by the study.
Secondary outcomes
1. Measures of cardiovascular risk factors such as change 
in smoking status, change in levels of physical activity, 
change in weight or BMI, change in diet, blood pressure, 
blood glucose or blood lipid levels.
2. Leaving the study early for any reason including inef-
ficacy of treatment, adverse events and death.
Databases
The following electronic databases were searched using 
NICE HDAS (Healthcare Databases Advanced Search): 
PsycINFO, MEDLINE and EMBASE. The search terms 
used for PsycINFO are provided in “Appendix”.2 To limit 
the results to RCTs, the Cochrane Highly Sensitive Search 
Strategies for identifying randomised trials were employed 
for each of PsycINFO, MEDLINE and EMBASE databases 
[32]. No date, language, document type or publication status 
limitations were applied to the search.
In addition, the Cochrane Central Register of Controlled 
Trials (CENTRAL) was searched via the Cochrane Library. 
The following clinical trials registries were also searched to 
identify any unpublished or ongoing trials: World Health 
Organisation International Clinical Trials Registry Platform 
(ICTRP), ISRCTN Registry, EU Clinical Trials Register 
(EudraCT) and ClinicalTrials.gov. The reference lists of any 
included papers would also have been examined.
Data collection and analysis
Selection of studies
Covidence, a web-based software platform designed to 
streamline the production of systematic reviews, was used 
to facilitate the selection of studies [33]. Electronic records 
identified from our search were imported to Covidence via 
Endnote X8 [34]. Two review authors (KH and KB) inde-
pendently screened all records identified from the search to 
identify potentially relevant papers for full-text review. Any 
disagreements were resolved by discussion among the two 
review authors; had this not been possible, it would have 
been further discussed with the senior author (PM).
Data extraction and management
In the event of relevant studies being identified, the two 
review authors planned to extract data from the included 
studies onto standardised forms.
Assessment of risk of bias in included studies
The two review authors planned to assess the risk of bias 
independently, using the Cochrane Risk of Bias tool [35]. 
Risk of bias level and trial quality would then have been 
noted in a ‘Summary of findings’ table.
Results
Description of studies
From our searches, 2045 electronic records were identified 
(Table 1).
Three hundred and five duplicates were removed by 
Covidence, leaving 1740 records for screening. One paper 
was obtained for full-text screening but was excluded after 
discussion between the three authors (KH, KB and PM) as, 
although a proportion of the study population had a diag-
nosis of PD, results for this group were not differentiated 
from the included individuals with other diagnoses. This 
published RCT, conducted by Knapen et al., described how 
Table 1  Results of database and 
trial registry searches Database Results
PsycINFO 379
MEDLINE 618
EMBASE 538
CENTRAL 479
Trial registries 31
Total 2045
2 Full search strategies for each database are available from the 
authors upon request.
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199 patients (70 of whom had a diagnosis of PD) were ran-
domly allocated to either a general programme of psychomo-
tor therapy (control) or a personalised psychomotor fitness 
programme (intervention), each lasting for 16 weeks. The 
intervention group showed an increase in cardiorespiratory 
fitness, but no subgroup analysis for the patients with PD 
was reported, or made available on request from the authors 
[36].
With regards to the trial registries search, no ongoing 
trials were identified which focused on people with PDs. As 
a result, no RCTs were eligible for inclusion in this review. 
This process has been summarised in a PRISMA flow dia-
gram (Fig. 1).
Discussion
We have argued that the modifiable risk factors associated 
with the development of CVD constitute an important tar-
get for narrowing the life expectancy gap between people 
with PD and the general population. The lack of identified 
trials in this area may partly be explained by the fact that 
the association between PD and CVD is less widely known 
compared to the association between CVD and other serious 
mental illnesses (SMI) [37].
In contrast to the paucity of trials in patients with PD, we 
have identified 10 systematic reviews investigating interven-
tions to improve the cardiovascular health or cardiovascular 
risk profile of people with SMI [38–47]. Moreover, most of 
these reviews did not include people with PD. We believe 
that excluding these people, who are at very high risk of 
CVD, is not only scientifically unsound but also represents 
a lost opportunity for developing an evidence base in a 
neglected field of health research.
Physical health appears to be under-assessed and under-
treated in people with PD [48]. Sanatinia et al. (2015) found 
that a lower proportion of those in a random sample of peo-
ple with PDs had documented evidence of smoking status, 
blood glucose and blood lipid levels compared to people 
with schizophrenia. Moreover, people with PD were less 
likely to be offered smoking cessation advice than those with 
schizophrenia [48].
Research in people with SMI may offer guidance on 
future productive trials for people with PD. If we take smok-
ing as an example, several trials (n = 26) relate to smok-
ing cessation in people with SMI, as shown by the recent 
Fig. 1  PRISMA flow diagram
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review by Peckham et al. [39]. It is noteworthy that peo-
ple with PD were excluded from this review. These trials 
often test relatively brief interventions, such as motivational 
interviewing. For example, Metse et al. conducted a cluster 
RCT of 754 adult psychiatric inpatients, 17.8% of whom 
had ‘personality and other disorders’ but with no further 
differentiation than this. They investigated the effect of a 
brief motivational interview and self-help material whilst in 
hospital, followed by a 4-month pharmacological and psy-
chosocial intervention upon discharge. No significant effect 
was found on measures of prolonged abstinence at either 6 
or 12 months, but intervention group participants were more 
likely than controls to have reduced cigarette consumption 
by 50% [49]. This suggests that there could be grounds for 
testing the effectiveness of a brief motivational intervention 
for smoking cessation among people with PD specifically.
The mode of treatment delivery is also important to con-
sider for people with PD, many of whom may lead turbulent 
and chaotic lives. It has already been established that the 
telephone is a feasible and acceptable mode of delivering 
interventions for people with PD, such as the use of tel-
ephone coaching in the context of dialectical behavioural 
therapy (DBT) [50]. Telephone-delivered smoking cessation 
has been trialled in people with psychosis; for example, in a 
RCT involving 235 smokers with psychotic disorders, Baker 
et al. (2018) found that both an individual ‘healthy lifestyle 
intervention’ (consisting of motivational interviewing and 
cognitive behavioural therapy over 6 months) and telephone-
delivered smoking cessation support achieved significant 
reductions in cardiovascular disease risk and smoking rates 
across a 36-month follow-up period [51]. Such telephone-
based interventions do not yet appear to have been trialled 
to improve cardiovascular risk factors in people with PD. 
However, the telephone could be a potentially promising 
delivery platform for a brief intervention designed to pro-
mote smoking cessation among people with PD. Ben-Porath 
(2004) hypothesises that telephone coaching in the context 
of DBT and self-harm provides a framework for encouraging 
patients to seek help in ‘more adaptive ways’ than their usual 
coping mechanisms [50]; this may well be applicable in the 
context of smoking in people with PD.
Smoking cessation is one example, but inspiration may be 
derived from a variety of approaches. Other trials in people 
with mental illness have aimed to reduce weight or waist 
circumference, for example by attempting to change the 
‘obesogenic environment’ of inpatient facilities, with some 
positive results in the short term though not the longer term 
[52]. Another example is the WebMOVE initiative in those 
with SMI, which consists of computerised weight-manage-
ment with peer coaching, which contributed to a reduction in 
BMI in the intervention group [53]. Further studies aimed to 
improve CVD risk more generally through lifestyle coaching 
[54, 55], or to improve access to physical healthcare via a 
peer health navigator scheme [56]. These interventions may 
be of interest when planning future work in those with PD.
Conclusion
There is a conspicuous gap in the literature on interventions 
designed to improve the cardiovascular health of people with 
PD, despite the significantly increased prevalence of CVDs 
and mortality in this population. The lack of studies in this 
field is particularly accentuated when compared to the extent 
of recent and ongoing research into physical health interven-
tions for people with other types of psychiatric disorders, 
such as psychotic or affective illnesses.
It is important to strive for parity of healthcare within 
psychiatric practice and this is particularly the case for peo-
ple with PD, who are so often still excluded from main-
stream healthcare. Our review shows that they are also 
excluded from trials evaluating the effectiveness of cardio-
vascular interventions. We believe that this is magnifying a 
serious public health problem, impacting both the quality of 
life of individuals with PDs and adversely affecting produc-
tivity in the context of wider health economics. We would 
argue that people with PD should be included in future trials 
of cardiovascular interventions. Such research could help to 
inform improvements in general health and mortality rates 
for people with this common and complex mental health 
disorder.
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Appendix: Example search strategy 
(PsycINFO)
((exp “PERSONALITY DISORDERS”/OR (“personality 
disorder*”).ti,ab OR (“personality patholog*”).ti,ab OR 
(“personality difficult*”).ti,ab OR (“disordered person-
alit*”).ti,ab OR (“borderline personalit*” OR “antisocial 
personalit*” OR “avoidant personalit*” OR “dependent 
personalit*” OR “histrionic personalit*” OR “narcissistic 
personalit*” OR “obsessive compulsive personalit*” OR 
“paranoid personalit*” OR “passive aggressive personalit*” 
OR “schizoid personalit*” OR “schizotypal personalit*”).
ti,ab OR (ICD AND (F60 OR F61 OR F62)).ti,ab OR (DSM 
AND (axis AND II)).ti,ab) AND (exp “CARDIOVASCU-
LAR DISORDERS”/OR exp “CARDIOVASCULAR SYS-
TEM”/OR exp “CARDIOLOGY”/OR exp “METABOLIC 
SYNDROME”/OR (“cardiovascular” OR “cardiometa-
bolic” OR “metaboli*” OR “myocardial” OR “heart dis-
ease” OR “stroke” OR “cerebrovascular” OR “ischaemi*” 
OR “ischemi*” OR “infarct*”).ti,ab OR exp “TOBACCO 
SMOKING”/OR exp “SMOKING CESSATION”/OR 
(“smok*” OR “cigarette*”).ti,ab OR exp DIETS/OR exp 
“DIETARY RESTRAINT”/OR exp “EATING BEHAV-
IOR”/OR exp “HEALTH BEHAVIOR”/OR exp NUTRI-
TION/OR (“diet*” OR “healthy eating”).ti,ab OR exp OBE-
SITY/OR exp OVERWEIGHT/OR exp “WEIGHT LOSS”/
OR exp “WEIGHT CONTROL”/OR (“obes*” OR “over-
weight” OR “waist circumference”).ti,ab OR exp “PHYSI-
CAL ACTIVITY”/OR exp “PHYSICAL FITNESS”/OR 
(“exercis*” OR “fitness” OR “physical activit*”).ti,ab OR 
exp “DIABETES MELLITUS”/OR exp “HYPERGLYCE-
MIA”/OR (“diabet*” OR “glucose” OR “hyperglycaemi*” 
OR “hyperglycemi*”).ti,ab OR exp HYPERTENSION/OR 
(“hypertens*” OR “blood pressure”).ti,ab OR (“cholesterol” 
OR “hypercholesterolaemi*” OR “hypercholesterolaemi*” 
OR “lipid*” OR “hyperlipidaemi*” OR “hyperlipidemi*”).
ti,ab)) AND (exp “TREATMENT EFFECTIVENESS 
EVALUATION”/OR (“random*” OR “control*”).ti,ab)
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